文献速递免疫规划

单次慢病毒载体DNA免疫可控制晚期异源SIVmac251黏膜攻击感染

A single lentivector DNA based immunization contains a late heterologous SIVmac251 mucosal challenge infection.
PubMed 文献 · Vaccine · 2020-04-09

研究在食蟹猴中评估单次整合缺陷型HIV慢病毒DNA疫苗免疫后18个月对异源致病性SIVmac251重复低剂量直肠攻击的保护效果。免疫组较对照组病毒载量峰值下降2个对数,并出现渐进且持续的病毒复制控制,该控制与抗原特异性CD4+和CD8+ T细胞的高容量回忆反应相关。作者认为该单次免疫策略未产生 sterilizing immunity,但似乎提供了有趣且安全的疫苗平台,值得进一步探索。

要点

  • 单次lentiDNA免疫后18个月,免疫组病毒载量峰值较对照组下降2个对数。
  • 免疫组显示渐进且持续的病毒复制控制,与抗原特异性CD4+和CD8+ T细胞回忆反应相关。
  • 作者认为该策略未产生 sterilizing immunity,但似乎提供有趣且安全的疫苗平台,值得进一步探索。

核心结论

  • 单次非整合单周期lentiDNA HIV疫苗免疫后18个月,在NHP模型中可控制SIV复制,但未产生 sterilizing immunity,作者认为该平台值得进一步探索。

研究设计与样本

  • 在食蟹猴中,单次免疫整合缺陷型HIV lentiDNA疫苗后18个月,所有动物接受重复低剂量直肠攻击异源致病性SIVmac251分离株。

主要发现

  • 免疫组食蟹猴病毒载量峰值较对照组下降2个对数,随后出现渐进且持续的病毒复制控制。
  • 抗病毒控制与抗原特异性CD4+和CD8+ T细胞的高容量回忆反应相关,包括效应和中枢记忆T细胞及记忆T细胞前体。

局限性

  • 作者指出该策略未产生 sterilizing immunity。
  • 作者认为该疫苗平台值得进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Variety of conventional vaccine strategies tested against HIV-1 have failed to induce protection against HIV acquisition or durable control of viremia. Therefore, innovative strategies that can induce long lasting protective immunity against HIV chronic infection are needed. Recently, we developed an integration-defective HIV lentiDNA vaccine that undergoes a single cycle of replication in target cells in which most viral antigens are produced. A single immunization with such lentiDNA induced long-lasting T-cell and modest antibody responses in cynomolgus macaques. Here eighteen months after this single immunization, all animals were subjected to repeated low dose intra-rectal challenges with a heterologous pathogenic SIVmac251 isolate. Although the viral set point in SIVmac-infected cynomolgus is commonly lower than that seen in Indian rhesus macaques, the vaccinated group of macaques displayed a two log reduction of peak of viremia followed by a progressive and sustained control of virus replication relative to control animals. This antiviral control correlated with antigen-specific CD4+ and CD8+ T cells with high capacity of recall responses comprising effector and central memory T cells but also memory T cell precursors. This is the first description of SIV control in NHP model infected at 18 months following a single immunization with a non-integrative single cycle lentiDNA HIV vaccine. While not delivering sterilizing immunity, our single immunization strategy with a single-cycle lentivector DNA vaccine appears to provide an interesting and safe vaccine platform that warrants further exploration.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chebloune Y, Moussa M, Arrode-Brusés G, et al. A single lentivector DNA based immunization contains a late heterologous SIVmac251 mucosal challenge infection. Vaccine. 2020. PMID: 32278522. doi:10.1016/j.vaccine.2020.03.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。